| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | FGFBP2 |
| Uniprot No | Q9BYJ0 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-223aa |
| 氨基酸序列 | MKFVPCLLLVTLSCLGTLGQAPRQKQGSTGEEFHFQTGGRDSCTMRPSSLGQGAGEVWLRVDCRNTDQTYWCEYRGQPSMCQAFAADPKPYWNQALQELRRLHHACQGAPVLRPSVCREAGPQAHMQQVTSSLKGSPEPNQQPEAGTPSLRPKATVKLTEATQLGKDSMEELGKAKPTTRPTAKPTQPGPRPGGNEEAKKKAWEHCWKPFQALCAFLISFFRG |
| 分子量 | 51 kDa |
| 蛋白标签 | GST-tag at N-terminal |
| 缓冲液 | 0 |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于重组人FGFBP2蛋白的3篇代表性文献及其摘要概括：
---
1. **文献名称**：*"FGFBP2 regulates tumorigenicity of melanoma cells by modulating the FGF2 signalling pathway"*
**作者**：Chen et al. (2018)
**摘要**：研究通过表达重组人FGFBP2蛋白，揭示其通过增强FGF2的稳定性及活性促进黑色素瘤细胞的增殖和迁移，提示其作为肿瘤治疗的潜在靶点。
2. **文献名称**：*"Recombinant human FGFBP2 facilitates angiogenesis in vitro and in vivo via interaction with FGF-2"*
**作者**：Liu et al. (2016)
**摘要**：利用哺乳动物细胞系统表达重组FGFBP2.证明其通过结合FGF-2促进内皮细胞血管生成，并加速小鼠缺血模型的血管修复，表明其在缺血性疾病中的潜在应用价值。
3. **文献名称**：*"Structural and functional characterization of recombinant human FGFBP2 produced in Escherichia coli"*
**作者**：Zhang et al. (2020)
**摘要**：报道在大肠杆菌中高效表达可溶性FGFBP2蛋白的方法，并通过X射线晶体学解析其结构，揭示其与FGF配体结合的关键区域，为后续功能研究奠定基础。
---
(注：以上为虚拟文献案例，实际研究中建议通过PubMed或Web of Science以“FGFBP2”及“recombinant protein”为关键词检索。)
Fibroblast Growth Factor Binding Protein 2 (FGFBP2) is a secreted molecular chaperone that interacts with fibroblast growth factors (FGFs), modulating their bioavailability and signaling in extracellular environments. First identified as part of the FGFBP family, FGFBP2 is implicated in tissue repair, angiogenesis, and tumor progression by facilitating FGF transport to receptors. Unlike its paralog FGFBP1. which is primarily linked to epithelial cancers, FGFBP2 shows broader expression in mesenchymal tissues and is often overexpressed in malignancies like breast and lung cancers, correlating with poor prognosis.
Recombinant human FGFBP2 (rhFGFBP2) is engineered using heterologous expression systems (e.g., E. coli or mammalian cells) to produce purified, bioactive protein for functional studies. Its recombinant form allows precise investigation of its role in FGF-dependent pathways, such as cell proliferation, migration, and wound healing. rhFGFBP2 is also explored for therapeutic applications, including enhancing tissue regeneration or blocking oncogenic FGF signaling. Challenges include optimizing protein stability and delivery mechanisms while minimizing off-target effects. Current research focuses on defining its structure-function relationships and validating its utility as a diagnostic biomarker or targeted therapy in FGF-driven diseases.
×
